2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Romnee Clark, MD

Senior Medical Director
Endocyte, Inc.
c/o National Corporate Research,  Ltd.
615 S. Dupont Highway
Dover, DE
USA 19901

Papers:
8 A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED) (NCT01170650)